-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Nurix Therapeutics, Raises Price Target to $32

Benzinga·10/13/2026 13:26:06
Listen to the news
Oppenheimer analyst Kostas Biliouris maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $28 to $32.